Xoma Royalty Corporation (XOMA) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Xoma Royalty Corporation  (NASDAQ: XOMA)


Xoma Royalty's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Xoma Royalty's ROI in the first quarter of 2026?
Xoma Royalty Corporation achieved a return on average invested assets (ROI) of 8.73 % in its first quarter of 2026, this is above XOMA's average return on investment of -635.55%.
Xoma Royalty Corporation invested over the 12 months ending in its first quarter of 2026 $228 million

ROI decreased relative to the period ending Dec 31 2025, due to the decline in net income.

Within the Healthcare sector 124 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Mar 31 2026 quarter, so far to 1055, from total ROI ranking in the fourth quarter of 2025 at 1175.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM 24.11 % 13.3 % 2.68 % 5.2 % 20.46 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 239 238 235 202 172
Return On Investment (TTM) 8.73 % 8.74 % 6.56 % -8.02 % -5.43 %
XOMA's Overall Ranking # 1055 # 1175 # 1126 # 3091 # 2993
Seq. Investment Change TTM 7.85 % 7.76 % 7.18 % -0.36 % -1.55 %
Seq. Net Income Change TTM 7.65 % 43.57 % - - -
Net Income (TTM) in Millions 20 19 13 -15 -10

XOMA Company Profile >> Back to XOMA Roi Comparisons >> See Annual XOMA Return On Investment



Return On Investment XOMA's Ranking
Within: No.
Industry # 47
Sector # 125
Overall # 1055

Return On Investment Statistics
High Average Low
41.18 %
-635.55 %
-31002.02 %
(Mar 31 2018)   (Jun 30 2017)







Financial Statements
Xoma Royalty's I. Quarter Investments $ 239 Millions XOMA's Balance sheet
Xoma Royalty's I. Quarter Income $ 2 Millions Quarterly XOMA's Income Statement
XOMA's Income by Division See XOMA's Income by Division


XOMA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 238 197 215 134 154
Y / Y Investment Growth 20.81 % -8.33 % 60.82 % -13.04 % 35.95 %
Net Income in Millions 19 -19 -46 -23 8
Y / Y Net Income Growth - - - - -11.44 %
Annual Return On Investment 7.78 % -9.8 % -21.56 % -16.9 % 5.07 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 7.78 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
XOMA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for XOMA's Competitors
Subscribers only: Roi for Xoma Royalty's Suppliers
Subscribers only: Return On Investment for XOMA's Customers

Other Ratios
XOMA's Roa XOMA's Inventory Turnover Ratio XOMA's Growth Rates XOMA's Dividend Statistics
XOMA's Profitability Ratios XOMA's Asset Turnover Ratio XOMA's Dividend Growth
XOMA's Roe XOMA's Valuation Ratios XOMA's Financial Strength Ratios XOMA's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI
Iradimed Corporation  23.59 %
Catalyst Pharmaceuticals Inc   23.58 %
Engene Therapeutics Inc   22.76 %
Protalix Biotherapeutics inc   22.70 %
Electromed Inc   22.36 %
Dexcom Inc   22.17 %
Illumina Inc   22.01 %
Pro dex Inc   20.88 %
Gilead Sciences Inc   20.52 %
Vertex Pharmaceuticals Inc  20.49 %
Agilent Technologies inc   20.46 %
Zoetis Inc   20.35 %
Resmed Inc   20.23 %
Soleno Therapeutics Inc  19.51 %
Krystal Biotech Inc   19.07 %
Puma Biotechnology Inc   18.83 %
United Therapeutics Corporation  18.64 %
Hca Healthcare Inc   18.54 %
Chemed Corporation  18.36 %
Apellis Pharmaceuticals Inc   17.94 %
Neurocrine Biosciences Inc   17.65 %
Halozyme Therapeutics Inc   17.53 %
Transmedics Group Inc   17.09 %
Inspire Medical Systems inc   16.60 %
Aveanna Healthcare Holdings Inc   16.38 %
Intuitive Surgical Inc   16.36 %
Alnylam Pharmaceuticals Inc   16.15 %
Strata Critical Medical Inc   16.15 %
Standard Biotools Inc   15.94 %
Profound Medical Corp   15.18 %

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.